Gene-panel sequencing and the prediction of breast-cancer risk

New England Journal of Medicine

Volumn 372, Issue 23, 2015, Pages 2243-2257

  Easton, Douglas F ^a   Pharoah, Paul D P ^a   Antoniou, Antonis C ^a   Tischkowitz, Marc ^a   Tavtigian, Sean V ^d   Nathanson, Katherine L ^e   Devilee, Peter ^f   Meindl, Alfons ^g   Couch, Fergus J ^h   Southey, Melissa ⁱ   Goldgar, David E ^d   Evans, D Gareth R ^b   Chenevix Trench, Georgia ^j   Rahman, Nazneen ^c   Robson, Mark ^k   Domchek, Susan M ^e   Foulkes, William D ^l  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; DNA GLYCOSYLASE MUTY; FANCONI ANEMIA GROUP C PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; RAD50 PROTEIN; UVOMORULIN;

ARTICLE; ATM GENE; BREAST CANCER; BRIP1 GENE; CANCER PROGNOSIS; CANCER RISK; CDH1 GENE; CHEK2 GENE; FANCC GENE; FANCM GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MEN1 GENE; MISSENSE MUTATION; MLH1 GENE; MRE11A GENE; MSH2 GENE; MSH6 GENE; MUTATIONAL ANALYSIS; MUTYH GENE; NBN GENE; NF1 GENE; PALB2 GENE; PMS2 GENE; PPM1D GENE; PRIORITY JOURNAL; PTEN GENE; RAD50 GENE; RAD51C GENE; RAD51D GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STK11 GENE; TP53 GENE; TUMOR SUPPRESSOR GENE; XRCC2 GENE; BREAST NEOPLASMS; DNA SEQUENCE; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GENOTYPING TECHNIQUE; HETEROZYGOTE; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; RISK; STANDARDS; UNITED STATES;

BREAST NEOPLASMS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOTYPING TECHNIQUES; GUIDELINES AS TOPIC; HETEROZYGOTE; HUMANS; RISK; SEQUENCE ANALYSIS, DNA; UNITED STATES;

EID: 84930531402     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsr1501341     Document Type: Article

References (75)

1. Assoc. for Molecular Pathology v. Myriad Genetics, Inc. 569 U.S. - (2013) (https://supreme.justia.com/cases/federal/us/569/12-398).
2. Grady D, Pollack A. Finding risks, not answers, in gene tests. New York Times, September 22, 2014 (http://www.nytimes.com/2014/09/23/health/finding-risks-not-answers-in-gene-tests.html?module=Search&mabReward=relbias%3Ar%2C{%222%22%3A%22RI%3A13%22}&-r=0).
3. Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In:Khoury MJ, Little J, Burke W, eds. Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. Oxford, United Kingdom:Oxford University Press, 2003:217-33.
4. National Institute for Health and Care Excellence. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. London: National Collaborating Center for Cancer, 2013 (http://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq#section/all).
5. Hayes DF, Allen J, Compton C, et al. Breaking a vicious cycle. Sci Transl Med 2013;5:cm6.
6. Sharfstein J. FDA regulation of laboratory-developed diagnostic tests: protect the public, advance the science. JAMA 2015;313:667-8.
7. Lander ES. Cutting the Gordian helix - regulating genomic testing in the era of precision medicine. N Engl J Med 2015;372:1185-6.
8. Evans BJ, Burke W, Jarvik GP. The FDA and genomic tests - getting regulation right. N Engl J Med 2015;372:2258-64.
9. Hollestelle A, Wasielewski M, Martens JW, Schutte M. Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev 2010;20:268-76.
10. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
11. Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and Web interface. Br J Cancer 2014;110:535-45.
12. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
13. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-22.
14. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11.
15. Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 2003;72:975-83.
16. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013;50:255-63.
17. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400-7.
18. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121:1348-53.
19. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006;12:3209-15.
20. Madanikia SA, Bergner A, Ye X, Blakeley JO. Increased risk of breast cancer in women with NF1. Am J Med Genet A 2012;158A:3056-60.
21. Seminog OO, Goldacre MJ. Age-specific risk of breast cancer in women with neurofibromatosis type 1. Br J Cancer 2015;112:1546-8.
22. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014;371:497-506.
23. Heikkinen T, Kärkkäinen H, Aaltonen K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 2009;15:3214-22.
24. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007;39:165-7.
25. Erkko H, Xia B, Nikkilä J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007;446:316-9.
26. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5.
27. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97:813-22.
28. Janin N, Andrieu N, Ossian K, et al. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 1999;80:1042-5.
29. Olsen JH, Hahnemann JM, Børresen-Dale AL, et al. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer 2005;93:260-5.
30. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(∗)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
31. CHEK2 Breast Cancer Case-Control Consortium. CHEK2∗1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from nine studies. Am J Hum Genet 2004;74:1175-82.
32. Weischer M, Nordestgaard BG, Pharoah P, et al. CHEK2∗1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 2012;30:4308-16.
33. Kilpivaara O, Vahteristo P, Falck J, et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004;111:543-7.
34. Zhang G, Zeng Y, Liu Z, Wei W. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumour Biol 2013;34:2753-7.
35. Hogervorst FB, Nederlof PM, Gille JJ, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003;63:1449-53.
36. Cancer incidence in five continents. Vol. X. Lyon, France: International Agency for Research on Cancer, 2013 (http://www.iarc.fr/en/publications/pdfs-online/epi/sp164/index.php).
37. Easton DF, Hopper JL, Thomas DC, et al. Breast cancer risks for BRCA1/2 carriers. Science 2004;306:2187-91.
38. Kraft P. Curses - winner's and otherwise - in genetic epidemiology. Epidemiology 2008;19:649-51.
39. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-9.
40. Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013;45:353-61.
41. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
42. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:(1)64-7.
43. Heikkinen K, Rapakko K, Karppinen SM, et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006;27:1593-9.
44. Tommiska J, Seal S, Renwick A, et al. Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer 2006;118:2911-6.
45. Mosor M, Ziółkowska-Suchanek I, Roznowski K, Baranowska M, Januszkiewicz-Lewandowska D, Nowak J. RAD50 gene mutations are not likely a risk factor for breast cancer in Poland. Breast Cancer Res Treat 2010;123:607-9.
46. He M, Di GH, Cao AY, et al. RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer. Breast Cancer Res Treat 2012;133:111-6.
47. Bartkova J, Tommiska J, Oplustilova L, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008;2:296-316.
48. Damiola F, Pertesi M, Oliver J, et al. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res 2014;16:R58.
49. Pelttari LM, Heikkinen T, Thompson D, et al. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 2011;20:3278-88.
50. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012;44:475-6.
51. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011;43:879-82.
52. Pelttari LM, Kiiski J, Nurminen R, et al. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. J Med Genet 2012;49:429-32.
53. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011;43:1104-7.
54. Thompson ER, Doyle MA, Ryland GL, et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet 2012;8(9):e1002894.
55. Kiiski JI, Pelttari LM, Khan S, et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci U S A 2014;111:15172-7.
56. Park DJ, Lesueur F, Nguyen-Dumont T, et al. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012;90:734-9.
57. Cybulski C, Carrot-Zhang J, Kluźniak W, et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet 2015;April 27 (Epub ahead of print).
58. Sun J, Wang Y, Xia Y, et al. Mutations in RECQL gene are associated with predisposition to breast cancer. PLoS Genet 2015;11(5):e1005228.
59. Win AK, Lindor NM, Jenkins MA. Risk of breast cancer in Lynch syndrome: a systematic review. Breast Cancer Res 2013;15:R27.
60. Out AA, Wasielewski M, Huijts PE, et al. MUTYH gene variants and breast cancer in a Dutch case-control study. Breast Cancer Res Treat 2012;134:219-27.
61. Dreijerink KM, Goudet P, Burgess JR, Valk GD. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med 2014;371:583-4.
62. Ruark E, Snape K, Humburg P, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 2013;493:406-10.
63. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007;81:873-83.
64. Lindor NM, Guidugli L, Wang X, et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 2012;33:8-21.
65. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004;75:535-44.
66. Plon SE, Eccles DM, Easton D, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008;29:1282-91.
67. Le Calvez-Kelm F, Lesueur F, Damiola F, et al. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res 2011;13:R6.
68. Goldgar DE, Healey S, Dowty JG, et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 2011;13:R73.
69. Tavtigian SV, Chenevix-Trench G. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility. Biomark Med 2014;8:589-603.
70. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J. Interaction between CHEK2∗1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet 2005;366:1554-7.
71. Antoniou AC, Spurdle AB, Sinilnikova OM, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008;82:937-48.
72. Nickels S, Truong T, Hein R, et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet 2013;9(3):e1003284.
73. Campa D, Kaaks R, Le Marchand L, et al. Interactions between genetic variants and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium. J Natl Cancer Inst 2011;103:1252-63.
74. Rudolph A, Milne RL, Truong T, et al. Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. Int J Cancer 2015;136(6):E685-E696.
75. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju091.